Welcome to our dedicated page for Immunocore Holdings Plc news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings Plc stock.
Immunocore Holdings Plc (IMCR) delivers pioneering T cell receptor therapies through its ImmTAX platform, targeting complex diseases in oncology and immunology. This dedicated news hub provides investors and industry observers with essential updates on the company's scientific advancements and corporate developments.
Access authoritative reporting on clinical trial progress, regulatory milestones, and strategic partnerships shaping Immunocore's position in biotherapeutics. The curated collection includes verified press releases covering drug candidate evaluations, financial disclosures, and technology innovations like the KIMMTRAK therapy for metastatic uveal melanoma.
Key content categories include updates on immuno-oncology research, infectious disease programs, and autoimmune treatment pipelines. Users will find analysis-neutral reporting on FDA interactions, collaborative research initiatives, and quarterly performance metrics essential for informed decision-making.
Bookmark this page for streamlined access to Immunocore's latest verified developments. Check regularly for real-time updates on groundbreaking TCR-based therapies and their impact on global healthcare solutions.
Immunocore (NASDAQ: IMCR) has presented initial data from the multiple ascending dose (MAD) portion of its Phase 1/2 STRIVE trial for IMC-M113V, a functional HIV cure candidate. The study included 16 HIV-positive participants across three dose cohorts (60 mcg, 120 mcg, and 300 mcg).
Key findings show that IMC-M113V was well-tolerated with no serious adverse events. The 300 mcg cohort showed promising results, with 2 out of 5 patients demonstrating viral control. Notably, these patients maintained viral loads around 200 c/mL at week 8, significantly better than the historical rate of 5%.
The trial revealed dose-dependent viral control after antiretroviral treatment interruption, with some patients showing reduced CD4+ T cell-associated HIV Gag RNA, indicating a reduction in active virus reservoir. Two patients remained off antiretroviral treatment for the entire 12-week interruption period, with one patient showing viral reduction to <50 c/mL at week 12 - an outcome typically seen in <1% of cases.
Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, has announced its participation in three major investor conferences in March 2025.
The company will be present at:
- The TD Cowen 45th Annual Healthcare Conference with a presentation on Tuesday, March 4, 2025, at 3:10 p.m. EST
- The Barclays 27th Annual Global Healthcare Conference for a fireside chat on Tuesday, March 11, 2025, at 3:00 p.m. EST
- The Jefferies Biotech on the Beach Summit for one-on-one and small group meetings on Wednesday, March 12, 2025
Interested parties can access live webcasts of the presentations through the 'Events & Presentations' section under 'Events' in the 'Investors' area of Immunocore's website. Replay options will be available for a time after the events.
Immunocore (NASDAQ: IMCR) reported Q4 2024 financial results with KIMMTRAK net sales of $84.1M and full-year sales of $310.0M. The company achieved 11 consecutive quarters of revenue growth and expanded to 14 new territories.
Q4 net loss was $23.8M ($0.47 per share) compared to $19.7M in Q4 2023. Full-year 2024 net loss was $51.1M ($1.02 per share) versus $55.3M in 2023. R&D expenses increased to $222.2M from $163.5M in 2023.
Key developments include:
- KIMMTRAK now approved in 39 countries and launched in 24
- First patient randomized in Phase 3 PRISM-MEL-301 trial
- Initiated Phase 1/2 trial of IMC-R117C for colorectal cancers
- Strong cash position of $820.4M as of December 31, 2024
- Repaid $50M Pharmakon loan in November 2024
Immunocore Holdings (Nasdaq: IMCR), a commercial-stage biotechnology company focused on immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025.
The company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss the financial results and provide updates on its business and portfolio. The webcast will be accessible through the 'Events' section of Immunocore's website, with a replay available for a time afterward.
Immunocore Holdings (Nasdaq: IMCR) outlined its strategic priorities for 2025, focusing on expanding KIMMTRAK's global reach and advancing its clinical portfolio. The company is currently enrolling three Phase 3 trials across multiple melanoma indications, with initial data readouts expected in 2026.
Key priorities include building a melanoma franchise through additional launches and increased community penetration, with KIMMTRAK now available in 23 countries. The company is advancing multiple clinical trials, including Phase 1/2 trials with brenetafusp combinations in ovarian and lung cancer, and ongoing dose escalation studies.
The company plans to submit clinical trial applications for two autoimmune disease candidates: IMC-S118AI for Type 1 diabetes in 2025 and IMC-U120AI for atopic dermatitis in 2026. Preliminary unaudited cash position was approximately $820 million as of December 31, 2024.
Immunocore Holdings plc (Nasdaq: IMCR) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The company, which specializes in developing transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, will deliver a presentation on Wednesday, January 15, 2025, at 8:15 a.m. PST.
The presentation will be accessible through a live webcast on the 'Events & Presentations' section of Immunocore's website under the 'Investors' tab. A replay of the presentation will be available for a time after the event.
Immunocore Holdings plc (Nasdaq: IMCR) has appointed Travis Coy as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. Coy transitions from his role as Non-Executive Director, which he held since September 2019, to become an Executive Officer.
Coy brings over 20 years of experience from Eli Lilly and Company, where he most recently served as Vice President, Head of Transactions and M&A, Corporate Business Development. His previous roles at Eli Lilly included leading business development for oncology and cardiometabolic diseases, financial leadership of the oncology business unit, Director of Investor Relations, and Director of Corporate Finance and Investment Banking.
The appointment leverages Coy's deep knowledge of Immunocore's operations and science, gained during his five-year tenure as a Non-Executive Director, to support the company's mission in delivering transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases.
Immunocore (IMCR) has initiated the Phase 1 trial of IMC-P115C, its first half-life extended ImmTAC candidate, with the first patient now dosed. IMC-P115C targets PRAME (PReferentially expressed Antigen in MElanoma) and shares the same CD3 effector and TCR specificity as brenetafusp, but is designed with an extended half-life to improve patient convenience through reduced treatment frequency.
The Phase 1 dose escalation trial will evaluate safety, pharmacokinetics, and clinical activity in HLA-A*02:01-positive patients with advanced cancers expressing PRAME. This marks Immunocore's sixth ImmTAC candidate to enter clinical trials, building upon their existing PRAME dataset from brenetafusp's Phase 1/2 trials.
Immunocore (IMCR) has initiated patient treatment in a Phase 1/2 trial for IMC-R117C, their fifth ImmTAC candidate, targeting PIWIL1 in colorectal and other gastrointestinal cancers. The trial will evaluate both monotherapy and combination treatments with standard care in HLA-A*02:01-positive patients with advanced solid tumors.
IMC-R117C represents the first immunotherapy program targeting PIWIL1, a cancer-testis antigen overexpressed in multiple malignancies, including colorectal cancer (CRC). The company estimates up to 20,000 colorectal cancer patients globally are positive for both PIWIL1 and HLA-A*02:01. This development addresses a significant unmet medical need, particularly in advanced colorectal cancer cases resistant to standard treatments.
Immunocore (NASDAQ: IMCR) and EORTC have initiated the first Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM), enrolling their first patient. The trial aims to evaluate if tebentafusp can prevent or delay relapse in high-risk uveal melanoma patients after primary treatment, compared to observation.
The open-label, international, multicenter trial will enroll 290 HLA-A*02:01-positive patients who have undergone surgery or radiotherapy. Participants will be randomized 1:1 to receive either tebentafusp for six months or observation. The study will assess overall survival, safety, tolerability, and explore ctDNA as a marker of residual disease.
Tebentafusp (KIMMTRAK®) is currently approved in 38 countries for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
FAQ
What is the current stock price of Immunocore Holdings Plc (IMCR)?
What is the market cap of Immunocore Holdings Plc (IMCR)?
